Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti- immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 6, 1997, Pages 675-690

  Racine Poon, Amy ^a   Botta, Luigi ^b   Chang, Tse Wen ^b   Davis, Frances M ^b   Gygax, Daniel ^b   Liou, Ruey S ^b   Rohane, Patricia ^b   Staehelin, Theophil ^b   Van Steijn, Augusta M P ^b   Frank, William ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CGP 51901; CHIMERIC ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; SALBUTAMOL; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; BODY WEIGHT; BREATHING DISORDER; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACODYNAMICS; POPULATION DYNAMICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 13144282659     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90087-4     Document Type: Article

References (20)

1. Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, et al. Can anti-IgE be used to treat allergy? Springer Semin Immunpathol 1993;15:51-73.
2. Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan DW Jr, Hamilton RG. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Biotechnology 1990;8:122-6.
3. Heusser ChH, Bews J, Brinkmann V, Delespesse G, Kilchherr E, Ledermann F, et al. New concepts of IgE regulation. Int Arch Allergy Appl Immunol 1991;94: 87-90.
4. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, et al. The effect of intravenous administration of a chimaeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics. J Clin Invest 1996;99:879-87.
5. Coyle AJ, LeGros G, Bertrand C, Tsuyuki S, Heusser ChH, Kopf M, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol 1995;13:54-9.
6. Brusselle GG, Kips JC, Tavenier GH, VanDer Heyden JG, Cuvelier CA, Pauwels RA, et al. Attenuation of allergic inflammation in IL-4 deficient mice. Clin Exp Allergy 1994;24:73-80.
7. Seth R, Motte P, Kehely A, Wimalawansa SJ, Self CH, Bellet D, et al. A sensitive and specific two-site enzyme-immunoassay for human calcitonin using monoclonal antibodies. J Endocrinol 1988;119:351-7.
8. Wilson MB, Nakane PK. Recent developments in the periodate method of conjugating horseradish peroxidase [HRPO] to antibodies. In: Knapp W, editor. Immunofluorescence and related staining techniques. Amsterdam: Elsevier/North-Holland; 1978. p. 215.
9. Holmes K, Fowlkes BJ. Immunofluorescence and cell sorting. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: Greene Publishing and Wiley-Interscience; 1991. p. 5.4.3.
10. Wojchowski DM, Sitkowski AJ. Hybridoma production by simplified avidin-mediated electrofusion. J Immunol Methods 1986;90:173-7.
11. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical method validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
12. Klein J. Immunology: the science of self-nonself discrimination. New York: John Wiley; 1982.
13. SAS Technical Report P-229. SAS/STAT software: changes and enhancements release 607. Cary (NC): SAS Institute; 1992. p. 287-368.
14. Trang JM, LoBuglio AF, Wheeler RH, Harvey EB, Sun L, Ghrayeb J, et al. Pharmacokinetics of a mouse/ human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients. Pharmacol Res 1990;7:587-92.
15. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
16. Shibata Y, Baba M, Kuniyuki M. Studies on the retention of passively transferred antibodies in man; II: antibody activity in the blood after intravenous or intramuscular administration of anti-HBs human immunoglobulin. Vox Sang 1983;45:77-82.
17. NONMEM Project Group. NONMEM users guide. San Francisco: University of California at San Francisco; 1989.
18. Holford NHG. Parametric models for the time course of drug action: the population approach. In: Rowlad M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities; 1992. p. 193-206.
19. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): Drug Intelligence Publications; 1979.
20. Lentner C, editor. Geigy scientific tables: heart and circulation. Vol. 5. 8th rev. ed. West Caldwell (NJ): Ciba-Geigy; 1990. p. 101.